Online Master's in Biomedical Engineering @ Case.edu
A Mighty Force - read full story

Available Technologies

For information on technology available for licensing or commercialization, awards, or project information, please contact the CCTRP program leadership and we would be pleased to answer any questions you may have. This is a partial list, so please feel free to contact the team to learn more about these or additional opportunities. When available, technologies with one-page overviews are linked to the technology title.

Additional technologies from the Coulter Network can be found here.

Here is a link to setup an easy 30 min phone call: https://calendly.com/fening/30min-zoom

Quick links: Devices | Diagnostics | Healthcare IT | Therapeutics


Devices

 

Gastrointestinal liner for diversion of intestinal contents

Steve Schomisch, assistant professor of surgery, and Jeff Marks, professor of surgery

People sometimes develop a wound connecting their intestine to their skin. This complication is incredibly debilitating and costly. The intestinal contents leak out onto the skin causing injury to the skin and muscle, dehydration and malnutrition, and there is currently no way to stop it. The researchers are developing a novel management strategy to greatly reduce the leak, which reduces cost of care and helps patients recover faster.

 

Enabling closed-loop baroreflex activation in the treatment of refractory hypertension

Jonathan Baskin, associate professor of otology head and neck and staff physician at the Louis Stokes Cleveland VA Medical Center, Dustin Tyler, the Kent H Smith Professor II of Biomedical Engineering, Gilles Pinault, assistant professor of surgery and staff physician at University Hospitals, and Steve Majerus, research scientist at the Louis Stokes Cleveland VA Medical Center

High blood pressure or hypertension is a serious health care problem associated with considerable morbidity and mortality. Physicians rely heavily on drugs to treat hypertension, but there is a significant and growing population that is drug-resistant. Their approach employs an implanted neuromodulatory system to address this unmet need. They have demonstrated efficacy of their novel stimulation system in an acute human model, however, a vital element in this treatment modality is sensing blood pressure.

 

Minimally invasive interfascicular nerve stimulation (MiiNS) system for chronic pain management

Dustin Tyler, Kent H. Smith Professor, biomedical engineering; and Jennifer Sweet, professor, neurological surgery

This is a drug-free technology to provide targeted, comfortable, worry-free relief to people suffering from long-term pain. The discomfort and emotional stress from pain affects a person’s activity, sleep, and ability to live a healthy life, leading to other serious health problems. Our Minimally Invasive Interfascicular Nerve Stimulation (MiiNS) technology provides a targeted, personally customized and comfortable treatment without side effects, addiction or surgical procedures. MiiNS can be implanted by a doctor during a simple office visit to provide long lasting pain relief.

 

3-D ultrasound imaging for ophthalmology

Faruk Orge, professor of ophthalmology and visual sciences at the School of Illustration of high-resolution, 3D microscopic ultrasound systemMedicine and pediatric division chief of ophthalmology at University Hospitals Cleveland Medical Center; and David Wilson, professor of biomedical engineering

This technology will be the first high-resolution, 3-D microscopic ultrasound system to provide novel visualizations of eye structures to better understand pathophysiology, plan treatments and assess treatment results. Ultrasound is an effective ophthalmic imaging method that allows structures behind the iris, including the lens and ciliary body, as well as key portions of the aqueous outflow system, to be seen. This region of the eye plays a critical role in glaucoma—which affects over 2.7 million people in the United States alone—and cataract, which are leading causes of reversible and irreversible blindness.

 


Diagnostics

 

 

TraumaChek: A field-deployable dielectric coagulometer for comprehensive assessment of trauma-induced coagulopathy

Anirban Sen Gupta, professor biomedical engineering; and Sanjay Ahuja, professor of pediatrics

TraumaChekTM is a miniaturized, multichannel, portable, handheld blood coagulation analyzer for early, rapid, and comprehensive assessment of trauma-induced coagulopathy to guide hemorrhage control, transfusion, and resuscitative management of trauma at the point-of-injury by first responders and at the point-of-care by hospital clinicians.

 

 

MIRCA-Dx: a revolutionary new way to assess targeted and genetic therapies for inherited red cell disorders

Umut Gurkan, the Warren E. Rupp Associate Professor of mechanical engineering, Pedram Mohseni, the Goodrich Professor of Engineering Innovation and chair of electrical, computer and systems engineering, and Sanjay Ahuja, professor of pediatric hematology/oncology and staff physician at University Hospitals

New genetic therapies can correct unhealthy red blood cells, but can’t assess the health and functional properties of the newly made red cells in a patient. The researchers offer a novel reproducible, portable diagnostic test for physicians and pharmaceutical companies to measure how well the new genetic therapies work for a red blood-cell disorder, such as sickle cell disease.

 

Novel positron emission tomography (PET) imaging agent for tumor detection and treatment

Susann Brady-Kalnay, professor of molecular biology and microbiology; and James Basilion, professor of radiology biomedical engineering and pathology.

Specific tumor detection is critically important in cancer imaging to avoid unnecessary biopsies to exclude false-positive findings and to allow treatment—or redirection of treatment—at earlier stages of the disease. Positron Emission Tomography (PET) imaging agents that specifically recognize tumor cells are necessary for improved imaging and subsequent evaluation of therapeutic efficacy independent of their metabolic rates. PTPµ is a novel imageable biomarker that can be used to specifically and more comprehensively detect and monitor aggressive invasive and metastatic tumors.

 

Point-of-care device for monitoring and diagnosis of oral cancer

Aaron Weinberg, associate dean for research, chair of the Department of Biological Sciences and professor; Umut Gurkan, assistant professor of mechanical and aerospace engineering; and Santosh Ghosh, senior research associate.

Oral cancer kills thousands in the United States and hundreds of thousands worldwide. Early detection is key to improved survival. Oral cancer is now diagnosed by tissue biopsy, followed by pathology review.

But biopsies are expensive, painful, can cause complications and are impractical, should monitoring be required.

The team’s novel technology builds on a recent discovery that the two proteins produced in early stages of oral cancer change their ratios in cancerous cells, and that the ratio could be used as a non-invasive diagnostic tool. The researchers have developed a point-of-care microfluidic device which, when connected to a smartphone, obtains ratio results within 15 minutes.

Advantages include the ability to: non-invasively swab and diagnose a lesion for cancer while the patient waits; determine if a biopsy is necessary; permit pre-malignant lesions to be monitored; perform the test in any dental or ear, nose and throat clinic as part of oral health check-up; and obtain results at one-tenth the cost of a biopsy and pathology review.

 

Robust nanobubble contrast agents for real-time ultrasound guided prostate cancer biopsy

Agata Exner, professor of radiology and biomedical engineering; and Jim Basilion, professor of radiology and biomedical engineering

This technology will enable a more efficient and effective prostate cancer diagnosis while building on the existing biopsy workflow and clinical ultrasound imaging technology. The nanobubble imaging agent will specifically target prostate cancer cells and serve as a beacon guiding the urologist, in real time, to possible tumors. Nanobubble-guided biopsies could identify tumors more accurately and could lead to fewer procedures, thus reducing risk, lowering costs and shortening the time to diagnosis and treatment.

 

Sickle cell disease biochip blood-cell adhesion test for emerging anti-adhesive therapies (OPTIONED)

Umut Gurkan, assistant professor of mechanical and aerospace engineering; and Jane Little, professor of medicine in the Department of Hematology and Oncology

Sickle cell disease biochip technology is a new microfluidic blood test that measures the stickiness of blood cells to blood vessel walls. This new blood test can be used as a companion diagnostic test platform for emerging anti-adhesive therapies to allow effective, personalized treatment and care for patients living with sickle cell disease.

 


Healthcare IT

 

LunIOTx: decision-support technology for predicting response to immunotherapy in lung cancer

Anant Madabhushi, the F. Alex Nason Professor II of biomedical engineering and director of the Center for Computational Imaging and Personalized Diagnostics

LunIOTx is a non-invasive decision-support technology that uses patented artificial intelligence and pattern recognition algorithms on routine CT scans to identify lung cancer patients who will or will not respond to immunotherapy. By identifying patterns on CT scans associated with response, LunIOTx can enable early identification of lung cancer patients in whom expensive immunotherapy can be avoided and who might be better candidates for chemo or radiation therapy.

 

LunIRiS: Decision support tool for lung nodule risk prediction on screening CT

Anant Madabhushi, the F. Alex Nason Professor II of biomedical engineering; and Robert Gilkeson, professor of radiology.

Each year, more than 20 million patients in the United States undergo a chest computer tomography (CT) exam. In nearly half of these exams, a pulmonary nodule will be identified.

While most of these nodules are benign, it is difficult to distinguish them from nodules that require treatment. As a result, many patients unnecessarily undergo more invasive diagnostic procedures, including surgical wedge resection.

The team’s novel technology, LunIRiS, is a computerized decision-support technology for use in conjunction with routine chest CT scans to reduce the high false-positive diagnostic rate associated with lung nodules. The technology could greatly reduce the number of unnecessary invasive diagnostic procedures. With advanced computational image-analytic and machine-learning tools, LunIRiS provides a risk score for improved quantitative assessment of lung nodules and has been shown to improve the diagnostic accuracy of human readers.

 


Therapeutics

 

BAFF CAR-NK cells for therapy of B cell malignancies

Reshmi Parameswaran, assistant professor of medicine, and Umut Gurkan, the Warren E. Rupp Associate Professor of mechanical engineering

B cell Activating Factor Chimeric Antigen Receptor-Natural Killer (BAFF CAR-NK) cells can specifically kill B cell cancers in a very effective manner with minimum side effects. This is a potential therapy to address patients not responding to current cancer treatments.

 

 

 

BG34-200: a potent immunotherapeutic for melanoma, osteosarcoma, pancreatic cancer and other solid tumor cancers

Mei Zhang, research assistant professor, biomedical engineering; and Alex Huang, professor of pediatrics and pathology

A significant fraction of patients with solid tumor cancers in metastatic and advanced settings do not respond to immunotherapies due to a lack of T-cell-inflamed tumor microenvironment. This botanical-derived non-toxic BG34-200 molecule can be intravenously injected to modulate macrophages and create a tumor microenvironment that is vital for the generation of antitumor T-cell responses. The team is launching a clinical trial targeting canine metastatic osteosarcoma (OS) to collect key and gap data in preparation for a First-In-Human clinical trial targeting pediatric and AYA OS.

 

NeutroStat: neutrophil-targeted nanomedicine for treating venous thromboembolism (VTE)

Evi Stavrou, assistant professor of medicine and staff physician at the Louis Stokes Cleveland VA Medical Center, and Anirban Sen Gupta, professor of biomedical engineering

The NeutroStat technology consists of a nanoparticle loaded with specific neutrophil signal inhibitory drugs. The nanoparticle can specifically target activated neutrophil-platelet complexes that are the hallmark of developing clot niche in venous thrombosis and weakens the clot growth by decreasing neutrophil-driven thrombotic mechanisms. 

 

Drug-Free targeted prostate cancer treatment with TNT (Targeted Nanobubble Therapy)

Agata Exner, professor of radiology and biomedical engineering; and Jim Basilion, professor of radiology and biomedical engineering

 

 

 

 

 

 

Drug free, low toxicity prostate cancer treatment using nanobubbles are targeted to the prostate specific membrane antigen (PSMA) biomarker overexpressed on prostate tumor cells. The nanobubbles are injected into the bloodstream and specifically seek out only the cancer cells. Once inside the target cell, the NBs remain trapped and can be excited with an ultrasound pulse. Exposure to ultrasound results in collapse of the bubbles, leading to a highly focused mechanical disruption of the cancer cells and cell death. The approach, which we call TNT – targeted nanobubble therapy - can fit into the existing clinical work flow and can be carried out with standard clinical ultrasound equipment. TNT can treat tumors without severe side effects, as it will be effective only when NBs are sonicated and will destroy only the cancer cells and not the surrounding healthy cells.

 

Photosorb: engineered sunscreen with single, multifunctional active ingredient

Vijay Krishna, assistant staff in Cleveland Clinic’s Department of Biomedical Engineering; and Edward Maytin, staff in Cleveland Clinic’s Department of Dermatology

Every year, more than one million new cases of skin cancer, including melanoma, are diagnosed in the United States. The primary cause is exposure to ultraviolet radiation (UV) from sunlight. Sunscreens can block UV, but increasing concerns about the health and environmental risks of chemical sunscreens now on the market underscores an urgent need for safer, more effective alternatives. A team from biomedical engineering and dermatology at Cleveland Clinic is developing a novel sunscreen (PhotoSorb) that appears to be safer and more stable than current sunscreens, and also has the potential to actually prevent skin cancers.

 

Pharmacokinetic-pharmacodynamic-efficacy and safety studies of humanized monoclonal antibodies to treat inflammatory and immune diseases

Yunmei Wang, associate professor of medicine, Xin Yu, the F. Alex Nason Professor of biomedical engineering, and Daniel Simon, professor of medicine and chief clinical and scientific officer and president of University Hospitals Cleveland Medical Center

They developed novel monoclonal antibodies (mAbs) against a key extracellular signaling protein, the myeloid related protein-14 (MRP-14, aka S100A9), that acts as a potent driver of inflammation and thrombosis. MRP-14 has been implicated in the pathogenesis of several human diseases including SLE, thrombosis, atherosclerosis and acute lung injury.

 

HXB-319 as an engineered mesenchymal stem cell (MSC) based treatment for the rare/orphan autoimmune disorder Goodpasture Syndrome

Hulya Bukulmez, associate professor of pediatrics and staff physician at MetroHealth, and John Chae, professor of biomedical engineering and vice president of research and sponsored programs at MetroHealth

They have developed a novel cell therapy (HXB-319) based on naked MSCs, engineered to enhance immune responses to reduce inflammation and its resulting organ damage. The work proposed will help to advance HXB-319 cell therapy toward clinical use by targeting systemic autoimmune inflammatory diseases that cause end-stage organ damage such as pulmonary hemorrhage and end-stage kidney disease.

 

 

Plant virus-like particle-based cancer immunotherapy (OPTIONED)

Nicole Steinmetz, Julian Kim

The researchers developed an “in situ vaccination” strategy to treat metastatic cancer, using a nanoparticle formed by the protein components of a plant virus. Direct administration of the therapeutic nanoparticle into identified tumors triggers a tumor-specific immune response, eradicating the treated tumor as well as distal metastatic sites. Immune memory protects patients from outgrowth of metastatic disease or recurrence. Support from CTTRP will provide a framework toward translation from preclinical models to clinical evaluation.